Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. [2006 Dec]

Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. [2006 Oct-Dec]

Rise of plasma ghrelin with weight loss is not sustained during weight maintenance. [2006 Oct]

Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. [2006 Oct]

Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification? [2006 Mar]

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. [2006 May]

Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. [2006 May 02]

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. [2006 May]

Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. [2006 Jan-Feb]

Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes. [2005 Dec]

[Influence of orlistat therapy on serum insulin level and morphological and functional parameters of peripheral arterial circulation in obese patients] [2005 Nov]

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. [2005 Dec]

Effect of orlistat in obese patients with binge eating disorder. [2005 Oct]

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. [2005 Nov]

A comparison of meal replacements and medication in weight maintenance after weight loss. [2005 Oct]

The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. [2005 Sep]

[Efficacy and safety of a short-time orlistat treatment in obese subjects] [2005 Apr-Jun]

Exercise training as an adjunct to orlistat therapy reduces oxidative stress in obese subjects. [2005 Aug]

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. [2005 Jun 15]

Effect of Orlistat in obese patients with heart failure: a pilot study. [2005 May-Jun]

Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. [2005 May 15]

A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. [2005 May]

Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size. [2005 May]

Effect of orlistat on cardiovascular disease risk in obese adults. [2005 May]

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. [2005 Jan]

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. [2004 Dec]

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. [2004 Aug]

Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. [2004 May]

Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels. [2005 Jan]

The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. [2004 Sep]

Addition of orlistat to conventional treatment in adolescents with severe obesity. [2004 Dec]

Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. [2004 Apr]

A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. [2004 Sep 15]

Effects of orlistat on obesity-related diseases - a six-month randomized trial. [2004 Sep]

What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. [2004 Aug]

Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. [2004 Aug]

Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations. [2004 Jun 01]

Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? [2004 Mar]

Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity. [2004 Mar 01]

The pathophysiology of faecal spotting in obese subjects during treatment with orlistat. [2004 Feb 01]

A systematic review of the clinical effectiveness of orlistat used for the management of obesity. [2004 Feb]

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. [2004 Jan]

Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. [2004 Jan]

Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. [2004 Jan]

Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. [2003 Nov]

Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. [2003 Dec]

Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. [2003 Nov]

The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. [2003 Oct]

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. [2003 Apr]

Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. [2003 Jun]

Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. [2003 May]

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. [2003 May]

Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. [2003 May]

Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. [2003 Apr 15]

Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. [2003 Jan]

[Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study] [2002 Sep]

Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. [2002 Nov]

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. [2002 Nov]

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. [2002 Nov]

Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. [2002 Sep]

Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. [2000 Oct]

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. [2002 Jul]

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. [2002 Jun]

Are soft tissue composition of bone and non-bone pixels in spinal bone mineral measurements by DXA similar? Impact of weight loss. [2002 Jan]

The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. [2002 Apr]

Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. [2002 Jan]

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. [2002 Jan]

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. [2001 Nov]

Orlistat inhibits dietary cholesterol absorption. [2001 Oct]

Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. [2001 Oct]

Influence of orlistat on bone turnover and body composition. [2001 Aug]

Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). [2001 Jul]

Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. [2001 Jun]

Weight change and blood coagulability and fibrinolysis in healthy obese women. [2001 Feb]

Comparative evaluation of fecal fat excretion induced by orlistat and chitosan. [2001 Jun]

Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. [2001 Jun]

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. [2001 Apr 01]

Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. [2000 Dec]

Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. [2000 Sep]

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. [2000 Sep]

Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor. [2000 May]

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. [2000 May 08]

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. [2000 Mar]

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. [2000 Jan]

Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers. [2000 Feb]

Orlistat in the long-term treatment of obesity in primary care settings. [2000 Feb]

Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. [1999 Sep-Oct]

The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. [1999 Sep]

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. [1999 Jun]

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. [1999 Jan 20]

Treatment with orlistat reduces cardiovascular risk in obese patients. [1998 Dec]

[Reduction of obesity and improvement in metabolic parameters by inhibition of intestinal lipases: current results with orlistat] [1998]

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. [1998 Aug]

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. [1998 Jul 18]

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. [1998 Apr]

Insulin and leptin concentrations in obese humans during long-term weight loss. [1997 Sep]

A one-year trial to assess the value of orlistat in the management of obesity. [1997 Jun]

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. [1996 Jul]

Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. [1995 Nov]

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. [1995 Apr]